Immunovant tumbles as Credit Suisse downgrades on lower M&A expectations
lcs813/iStock via Getty Images
- Immunovant (IMVT -23.6%
) has extended the pre-market losses after Credit Suisse downgraded the stock to underperform from neutral, citing lower near-term M&A expectations due to $200M strategic investment received from the majority…
